WO2007130725A3 - Use of hmgb1 for protection against ischemia reperfusion injury - Google Patents

Use of hmgb1 for protection against ischemia reperfusion injury Download PDF

Info

Publication number
WO2007130725A3
WO2007130725A3 PCT/US2007/061709 US2007061709W WO2007130725A3 WO 2007130725 A3 WO2007130725 A3 WO 2007130725A3 US 2007061709 W US2007061709 W US 2007061709W WO 2007130725 A3 WO2007130725 A3 WO 2007130725A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmgb1
protection against
reperfusion injury
ischemia reperfusion
against ischemia
Prior art date
Application number
PCT/US2007/061709
Other languages
French (fr)
Other versions
WO2007130725A2 (en
Inventor
Allan Tsung
Timothy R Billiar
Mitchell P Fink
Kevin J Tracey
Original Assignee
Univ Pittsburgh
The Feinstein Inst Medical Res
Allan Tsung
Timothy R Billiar
Mitchell P Fink
Kevin J Tracey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh, The Feinstein Inst Medical Res, Allan Tsung, Timothy R Billiar, Mitchell P Fink, Kevin J Tracey filed Critical Univ Pittsburgh
Publication of WO2007130725A2 publication Critical patent/WO2007130725A2/en
Publication of WO2007130725A3 publication Critical patent/WO2007130725A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.
PCT/US2007/061709 2006-02-06 2007-02-06 Use of hmgb1 for protection against ischemia reperfusion injury WO2007130725A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76554506P 2006-02-06 2006-02-06
US60/765,545 2006-02-06

Publications (2)

Publication Number Publication Date
WO2007130725A2 WO2007130725A2 (en) 2007-11-15
WO2007130725A3 true WO2007130725A3 (en) 2008-04-10

Family

ID=38668413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/061709 WO2007130725A2 (en) 2006-02-06 2007-02-06 Use of hmgb1 for protection against ischemia reperfusion injury

Country Status (2)

Country Link
US (1) US7829097B2 (en)
WO (1) WO2007130725A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004266654B2 (en) 2003-08-12 2011-07-21 Loma Linda University Medical Center Modular patient support system
DK2055308T3 (en) * 2006-10-30 2017-07-17 Genomix Co Ltd PHARMACEUTICALS FOR PROMOTING FUNCTIONAL REGENERATION OF DAMAGED TISSUE
BRPI0911513A2 (en) 2008-04-30 2016-07-12 Genomix Co Ltd Methods and Agents for High-Efficiency In vivo Functional Bone Marrow Stem Cell Collection
WO2011052668A1 (en) 2009-10-28 2011-05-05 株式会社ジェノミックス Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
EA023058B1 (en) 2010-01-21 2016-04-29 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Vaccine vectors and methods of enhancing immune responses
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
JP6069191B2 (en) * 2011-04-26 2017-02-01 株式会社ジェノミックス Peptides and their use to induce tissue regeneration
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104884076B (en) * 2012-10-25 2017-10-03 吉诺米克斯股份有限公司 It make use of the treatment method of the miocardial infarction of HMGB1 fragments
AU2013335685B2 (en) 2012-10-25 2017-10-12 Osaka University Novel method for treating spinal cord injury using HMGB1 fragment
PT2956165T (en) 2013-02-14 2019-11-29 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20190015712A (en) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 Yeast vaccine vectors comprising immunostimulatory and antigenic polypeptides, and methods of using the same
WO2018139562A1 (en) * 2017-01-27 2018-08-02 株式会社ジェノミックス Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
US20210163552A1 (en) * 2017-04-25 2021-06-03 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
CN111542335A (en) 2017-12-01 2020-08-14 斯特姆里姆有限公司 Therapeutic agent for inflammatory bowel disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026691A2 (en) * 2001-09-25 2003-04-03 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for the activation of dendritic cells
WO2004004763A2 (en) * 2002-07-03 2004-01-15 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004061456A2 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of hmgb, hmgn, hmga proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
ITMI20010562A1 (en) 2001-03-16 2002-09-16 Marco E Bianchi HMG1 PROTEIN INHIBITORS OR ANTAGONISTS FOR THE TREATMENT OF VASCULAR DISORDERS
CA2447576C (en) 2001-05-15 2014-04-08 North Shore-Long Island Jewish Research Institute Use of hmg fragments as anti-inflammatory agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026691A2 (en) * 2001-09-25 2003-04-03 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for the activation of dendritic cells
WO2004004763A2 (en) * 2002-07-03 2004-01-15 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004061456A2 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of hmgb, hmgn, hmga proteins

Also Published As

Publication number Publication date
US7829097B2 (en) 2010-11-09
US20080004207A1 (en) 2008-01-03
WO2007130725A2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
WO2007130725A3 (en) Use of hmgb1 for protection against ischemia reperfusion injury
WO2007121188A3 (en) Compositions and methods of using r(+) pramipexole
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008014200A3 (en) Cyclosporin compositions
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008021368A3 (en) Compositions and methods for neuroprotection
PL2233127T3 (en) Use of antioxidants for the preparation of pharmaceutical or cosmetic compositions for protecting the skin from damages by infrared-radiations
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
EA201300005A1 (en) MODULING IMMUNOSUPRESSION COMPOUNDS
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
PT2233127T (en) Use of antioxidants for the preparation of pharmaceutical or cosmetic compositions for protecting the skin from damages by infrared-radiations
WO2009085889A3 (en) Compositions and methods for reducing or preventing water loss from the skin
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008052005A3 (en) Compounds and methods for treating estrogen receptor-related diseases
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009022077A3 (en) Use of hesperidin or of a derivative thereof for the prevention and/or treatment of slackened skin
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2009099467A3 (en) Cyclosporin compositions
WO2006129318A3 (en) Benzofuran derivatives with therapeutic activities

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07797125

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07797125

Country of ref document: EP

Kind code of ref document: A2